Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

In addition, the company just acquired Ambry Genetics for hereditary cancer tests helping Tempus AI expand into other areas such as rare disorder, pediatrics and cardiology. Tempus AI recently ...

The Pimax Crystal Light has some of the most stunning VR visuals of any headset we've tested thanks to some beautiful QLED displays. In many ways, it's a dying breed of PC VR headset that doesn't ...

Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expecting to close the Ambry acquisition in Q1 2025. The deal will be accretive to Tempus' adjusted EBITDA margin while ...